GlassScriptPhysician profile
Jackie S Beene
NPI 1841296548
$10,783.28
in general payments reported to CMS, 2019-2025
38 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,639 · 2020: $458 · 2021: $398 · 2022: $1,550 · 2023: $1,024 · 2024: $528 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,398.11 | 2019-2025 | Vraylar, Mavyret, Linzess |
| Novo Nordisk INC | $502.42 | 2019-2024 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $436.82 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $411.27 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $370.55 | 2019-2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $364.73 | 2019-2024 | Breztri, Farxiga, Tezspire |
| Pfizer INC. | $307.02 | 2019-2023 | |
| Amgen INC. | $300.64 | 2019-2024 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.40 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $204.62 | 2019-2024 | Jardiance, Trulicity, Mounjaro |
| Indivior INC. | $159.71 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $137.58 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.38 | 2022-2023 | |
| Dexcom, INC. | $93.28 | 2022-2023 | Dexcom G7 Gss (161) |
| Nestle Healthcare Nutrition INC. | $90.36 | 2020-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Beene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.